AcruxASX:ACR +8.33% Return-on-Tangible-Equity is 29.69% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 1,200 Biotechnology companies, Acrux ranks worse than 78.08% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Acrux's annualized net income for the quarter that ended in Dec. 2025 was A$0.33 Mil. Acrux's average shareholder tangible equity for the quarter that ended in Dec. 2025 was A$1.11 Mil. Therefore, Acrux's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 29.69%.
The historical rank and industry rank for Acrux's Return-on-Tangible-Equity or its related term are showing as below:
ASX:ACR'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -276.58 Med: -49.68 Max: 57.49
Current: -125.44
During the past 13 years, Acrux's highest Return-on-Tangible-Equity was 57.49%. The lowest was -276.58%. And the median was -49.68%.
ASX:ACR's Return-on-Tangible-Equity is ranked worse than 78.08% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs ASX:ACR: -125.44
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Acrux Return-on-Tangible-Equity Related Terms
Acrux Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Acrux's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ACR vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Acrux's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrux Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrux's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Acrux's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 29.69% mean?
Acrux (ASX:ACR) has a Return-on-Tangible-Equity of 29.69% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Acrux and its competitors. According to the industry distribution chart, Acrux ranks #937 out of 1200 companies in the Biotechnology industry, placing it in the top 78.1%.
Is Acrux's Return-on-Tangible-Equity too high?
Acrux's current Return-on-Tangible-Equity is 29.69%. Based on the distribution chart, Acrux ranks #937 out of 1200 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Acrux's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acrux ranks #937 out of 1200 companies for Return-on-Tangible-Equity. This places Acrux in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Acrux and its competitors. Acrux's current Return-on-Tangible-Equity is 29.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrux stock overvalued right now?
Based on GuruFocus' analysis, Acrux (ASX:ACR) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.03, compared to a current price of A$0.01 — trading 56.7% below its estimated fair value. The current Return-on-Tangible-Equity is 29.69%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Acrux (ASX:ACR), the current Return-on-Tangible-Equity is 29.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acrux Ltd is a dynamic Australian drug delivery specialist with expertise in developing and commercialising patient-preferred healthcare products for world-wide markets. Its talent creates value through the development and commercialisation of healthcare products using owned or acquired technologies. The group's products are patient preferred, protected by patent or other means, and use creative drug delivery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACR has been successfully added to your 